U.S. markets open in 34 minutes

Seelos Therapeutics, Inc. (SEEL)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3051-0.6949 (-69.49%)
At close: 04:00PM EDT
0.2707 -0.03 (-11.27%)
Pre-Market: 08:55AM EDT

Seelos Therapeutics, Inc.

300 Park Avenue
2nd Floor
New York, NY 10022
United States
646 293 2100

Full Time Employees16

Key Executives

NameTitlePayExercisedYear Born
Dr. Raj Mehra J.D., Ph.D.Founder, Chairman, CEO & Pres854.73kN/A1960
Mr. Michael J. GolembiewskiChief Financial Officer454.83kN/A1972
Ms. Kimberly FarrandSr. Director of Clinical Devel. & OperationsN/AN/AN/A
Mr. Anthony MarcianoChief Communications OfficerN/AN/AN/A
Gopal Krishna Ph.D.Head of Manufacturing & Technical OperationsN/AN/AN/A
Tim Whitaker M.D.Chief Medical OfficerN/AN/AN/A
Ms. Karen FusaroSr. VP & Head of Clinical OperationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.

Corporate Governance

Seelos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.